Ensemble Therapeutics

Ensemble Therapeutics is a startup based in the United States. Its most recent tracked round is Series B. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

Ensemble Therapeutics was a biopharmaceutical company founded in 2003 that developed a novel class of macrocyclic therapeutics called Ensemblins™ to target drug binding sites inaccessible to conventional small molecules. The company ceased operations in 2017.